BCS Wealth Management Buys 400 Shares of Regeneron Pharmaceuticals Inc (REGN)

BCS Wealth Management initiated a new position in Regeneron Pharmaceuticals Inc (REGN) with 400 shares valued at approximately $308,750. The biotech company reported Q4 earnings of $11.83 per share, beating analysts' expectations of $3.59 billion in revenue. REGN has a market capitalization of $79.20 billion, a P/E ratio of 18.04, and a beta of 0.48.